- Home
- CR vs VTRS Comparison
CR vs VTRS Comparison
Compare CR & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CR
- VTRS
- Stock Information
- Founded
- CR 1855
- VTRS 1961
- Country
- CR United States
- VTRS United States
- Employees
- CR N/A
- VTRS N/A
- Industry
- CR Metal Fabrications
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- CR Industrials
- VTRS Health Care
- Exchange
- CR Nasdaq
- VTRS Nasdaq
- Market Cap
- CR 10.9B
- VTRS 12.2B
- IPO Year
- CR N/A
- VTRS N/A
- Fundamental
- Price
- CR $184.74
- VTRS $10.76
- Analyst Decision
- CR Strong Buy
- VTRS Hold
- Analyst Count
- CR 5
- VTRS 6
- Target Price
- CR $223.60
- VTRS $11.17
- AVG Volume (30 Days)
- CR 299.9K
- VTRS 9.1M
- Earning Date
- CR 10-27-2025
- VTRS 11-06-2025
- Dividend Yield
- CR 0.50%
- VTRS 4.40%
- EPS Growth
- CR 37.96
- VTRS N/A
- EPS
- CR 6.25
- VTRS N/A
- Revenue
- CR $2,268,100,000.00
- VTRS $14,124,400,000.00
- Revenue This Year
- CR $10.97
- VTRS N/A
- Revenue Next Year
- CR $12.81
- VTRS $1.61
- P/E Ratio
- CR $33.59
- VTRS N/A
- Revenue Growth
- CR 19.64
- VTRS N/A
- 52 Week Low
- CR $127.04
- VTRS $6.85
- 52 Week High
- CR $203.89
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- CR 44.71
- VTRS 57.42
- Support Level
- CR $187.36
- VTRS $9.92
- Resistance Level
- CR $191.85
- VTRS $11.28
- Average True Range (ATR)
- CR 5.84
- VTRS 0.35
- MACD
- CR -0.77
- VTRS 0.04
- Stochastic Oscillator
- CR 35.32
- VTRS 61.43
About CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.